The operating profit increased to R3.1 billion (US$179.77m), reflecting strong operational performance in both acute and non-acute businesses.
This consisted of a 5% increase in southern African revenue to R20 billion (US$1.16b) and a 2.8% increase in international revenue from continuing operations to R7.7 billion (US$446.51m).
The southern African business saw better activity levels, with a strong recovery in a broad range of surgical and medical activities, resulting in a 9.1 % increase in paid patient days (PPDs), and increased occupancy of 64.5% in the second half of the year.
Excellent progress has also been made in advancing strategic initiatives to grow non-acute areas of the business for the year under review.
The International business-maintained delivery of underlying growth of c.10%, and the Group expects demand for diagnostic imaging and radiopharmacy services to grow as the UK and Europe continue to promote healthcare policies that lead to earlier diagnosis of cancer and other diseases.
There remains good growth in sales of Radiopharmaceuticals within Northern Europe.
“We demonstrated significant progress this year in executing on our long-term strategy, and we are well-positioned for sustainable growth in 2023 and beyond,” Group Chief Executive, Peter Wharton-Hood, said.
“The Group maintains its momentum, and we continue to demonstrate our resilience with robust cash generation and a strong balance sheet.”
The Group remains in a strong financial position, with net debt to normalised EBITDA below 2x, as at 30 September 2022.
They also launched its inaugural listed corporate bond programme in 2022, which was oversubscribed 4.8 times, indicative of the significant institutional and bank interest in the Company.
The Group’s 2026 strategy is underpinned by an efficient and resilient acute hospital business in southern Africa that is highly cash-generative, delivering high-quality healthcare through a remarkable complement of nurses, doctors and other healthcare professionals.
Growth in non-acute business lines continues to be a combination of organic and acquisitive growth to diversify service offerings, reflected through the acquisition of the non-clinical operations of the East Coast Radiology and the Eugene Marais Radiology businesses in South Africa. 2022 has been a significant year in building on this foundation and expanding the Group’s revenue mix.
The diversification strategy also allows the Group to bring its global expertise of running a radiopharmacy business to South Africa through the joint venture with AXIM to initially build two cyclotrons.
“Having weathered the storm, we are bullish about volume growth in H1 2023 and expect to see PPD volumes grow between 5% to 6% in southern Africa. We also anticipate growth of between 5% to 7% in our UK and European diagnostic imaging market,” Wharton-Hood said.
“None of this can be achieved without the committed support of our people, who continue to demonstrate remarkable agility and resilience in the face of ongoing adversity, globally. We thank them.”